Incidence of hyperbilirubinemia and jaundice due to atazanavir in a cohort of Hispanic patients.

about

Incidence of hyperbilirubinemia and jaundice due to atazanavir in a cohort of Hispanic patients.

Item

http://www.wikidata.org/entity/Q43240844

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Incidence of hyperbilirubinemi ...... a cohort of Hispanic patients.

@en

Incidence of hyperbilirubinemi ...... a cohort of Hispanic patients.

@nl

type

Item

label

Incidence of hyperbilirubinemi ...... a cohort of Hispanic patients.

@en

Incidence of hyperbilirubinemi ...... a cohort of Hispanic patients.

@nl

prefLabel

Incidence of hyperbilirubinemi ...... a cohort of Hispanic patients.

@en

Incidence of hyperbilirubinemi ...... a cohort of Hispanic patients.

@nl

P1476

Incidence of hyperbilirubinemi ...... a cohort of Hispanic patients.

@en

P2093

Emiliano Bissio

http://www.w3.org/2001/XMLSchema#string

Gustavo D Lopardo

http://www.w3.org/2001/XMLSchema#string

P2860

Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1

Efficacy and safety of once-daily regimens in the treatment of HIV infection.

Atazanavir: its role in HIV treatment

Clinical pharmacology, efficacy and safety of atazanavir: a review.

Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER Cohorts.

Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects.

Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results.

Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir.

Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.

P304

415-417

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1089/AID.2012.0233

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-11-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23121190

http://www.w3.org/2001/XMLSchema#string

P921

bilirubin metabolic disorder

P932

3581036

http://www.w3.org/2001/XMLSchema#string